October 13th 2010, Lysaker, Norway ? A recent review article, published by Rees et al at University of Warwick, (Maturitas 67 (2010) 121?128) reaffirms that high intake of vitamin K2 (and not K1) decreases the number of cardiovascular events and mortality.
A systematic review of the literature was performed in January 2010. The authors applied strict quality checks for the papers taken up in the review and five good quality studies met the inclusion criteria (1 trial and 4 cohort analyses).
No associations were found between vitamin K1 intake and Coronary heart disease (CHD) (4 cohorts) and stroke (2 cohorts). However; two cohorts found significant associations where higher vitamin K2 intake was associated with fewer CHD events and mortality. The beneficial effects seem to be associated with the long chain menaquinones MK?7 to MK?9). In other words, NattoPharma?s MenaQ7 (MK?7) is again supported with high quality scientific evidence. CEO Morten Sundst? of NattoPharma comments: ?The area of Cardivascular diseases is extremely exciting for MenaQ7, and as we also have a solid patent portfolio covering food supplement, functional food and pharma in this area we now enjoy exciting product development discussions with key players. ?
The authors point out the importance of more placebo?controlled intervention studies in which the beneficial effect of vitamin K2 is demonstrated in the healthy population and in patients. NattoPharma presently run several clinical trials and is proud to contribute to this important research.
Professor Cees Vermeer, leader of VitaK, the largest research group on vitamin K worldwide says: ? I am very happy with the review because it confirms that all evidence presently available indicates that increased vitamin K2 intake decreases cardiovascular disease and improves survival. Moreover the review is consistent with at least five different studies from our lab in which we assessed vascular vitamin K status by monitoring MGP carboxylation; all these studies showed that better vitamin K status is associated with strongly improved survival.?
For more information: CEO Morten Sundst? Tel: +47 950 61860
Tel.: (+47) 67 20 02 50 [email protected] www.nattopharma.comPRESS RELEASE | Date: October 13th 2010
MenaQ7 provides natural vitamin K2 as a fermentation extract whereby vitamin K2 is manufactured using bascillus subtilis natto. This process has the capacity of producing the highly pure and bio?available form of vitamin K2, menaquinone?7 (MK?7). MenaQ7 is the best documented, commercially available natural vitamin K2 with guaranteed actives and stability, clinical substantiation and international patents granted and pending.
For more information on the health benefits of MenaQ7, please visit www.menaq7.com
NattoPharma, Norway is the exclusive international supplier of MenaQ7, the natural Vitamin K2. NattoPharma has entered into a multi?year research and development program to substantiate and discover the health benefits of natural vitamin K2 for applications in the exciting marketplace for functional food and health food supplements.
For more information, please visit www.nattopharma.com